AmethIntel
Example dashboard: CEACAM5
Bring the data to the deal table.
Which tumours each modality is going after
Counts by tumour type and modality. Two of twelve tumour types are shown here.
| Tumour type | ADC | Bispecific | CAR-T | Total |
|---|---|---|---|---|
| Colorectal | 3 | 5 | 6 | 14 |
| Lung | 7 | 1 | – | 8 |
| Ten more tumour types are mapped in the report. | ||||
| Total | 28 | 8 | 24 | 60 |
What the enrichment criterion leaves out
New US cases a year in tumour types that express CEACAM5.
About 90,000 of 800,000fall inside the criterion current trials use
- About 90,000 selected: 40% of colorectal and 15% of non-small-cell lung patients, at 50% or more of cells staining 2+ on IHC.
- About 710,000 not yet tested by the leaders.
Patent landscape
Broad but permeable.
- 1,000+ patents screened across antibodies, payloads, linkers and ADCs.
- Barriers to a new entrant are low. Coverage is wide, not deep.
Source: CEACAM5 report, patent chapter. Not a formal FTO opinion.
Adjacent areas
What other targets already taught the market.
- HER2/neu shows the urgency, and the value of diagnostics as the gating asset.
- EGFR and other oncogenes are the next wave, and a route to market expansion.
Highest-impact areas, as of mid-2026
What the analysis points to, and what the report provides for each.
- Improved diagnosticsAlternative designs proposed.Section 9
- Trial designs optimised for the regulatory pathAlternative designs proposed.Sections 3 and 10
- Realistic valuation from the patent landscapeDue-diligence cheat sheets included.Sections 6, 7 and 8
- Trial planning that plays to ADC strengthsPlanning approach set out.Section 5
Our read of the data
The alternative designs, the rankings and the reasoning behind them. Shared in full under a CDA, or with the report.
Read the free executive summary© 2026 AmethIntel (Amethos Pharma Pvt. Ltd.). Not for recirculation.
This is the dashboard a client receives within 48 hours, shown here for CEACAM5 with the interpretation locked. Every finding traces to a patent, a registered trial or a peer-reviewed paper.